27 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.
502 citations
,
February 2008 in “The Journal of Clinical Endocrinology & Metabolism” This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.
129 citations
,
October 2007 in “The New England Journal of Medicine” This article discusses the evaluation and management of a 45-year-old woman with diffuse scalp-hair loss and reports no new clinical findings.
1744 citations
,
August 2006 in “The Journal of Clinical Endocrinology and Metabolism” This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.
271 citations
,
December 2005 in “New England journal of medicine/The New England journal of medicine” This article discusses evaluation and treatment options for a 19-year-old woman with slowly progressive hair growth and reports no new clinical findings.
8 citations
,
September 2005 in “Practical diabetes” This article discusses management strategies for polycystic ovary syndrome, emphasizing the role of insulin resistance and the importance of addressing associated cardiovascular risk factors; it reports no new clinical results.
39 citations
,
August 2004 in “International journal of gynaecology and obstetrics” This study found that both finasteride and a regimen of cyproterone acetate plus ethinyl estradiol effectively reduced hirsutism in women, with similar results despite differing hormonal effects.
4809 citations
,
January 2004 in “Fertility and Sterility” This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.
56 citations
,
April 2003 in “Fertility and Sterility” This study found that while cyproterone acetate, finasteride, and spironolactone had similar short-term effects in treating idiopathic hirsutism, spironolactone provided more lasting benefits one year after treatment.
63 citations
,
March 2001 in “Fertility and Sterility” This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.
55 citations
,
March 2000 in “American journal of clinical dermatology” Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.
142 citations
,
February 1985 in “Fertility and sterility” This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.